Condition: NSCLC · Sponsor: The First Affiliated Hospital of Zhengzhou University
Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC
This description comes directly from the study's public registry record.
Feng Li, MD · +8615838222689 · LF_0604@163.com
Yu Qi · +8613803892392 · qiyu@zzu.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhengzhou University, | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05286957